STAAR Surgical Company - 10-K Summary (Fiscal Year Ended Dec 28, 2001)
Business Context and Reporting Period
STAAR Surgical Company (Nasdaq: STAA) is a developer, manufacturer, and global distributor of ophthalmic products, including Intraocular Lenses (IOLs), Implantable Contact Lenses (ICLs), and the AquaFlow Glaucoma Drainage Device. The company operates as a single business segment, with the cataract market remaining its primary revenue source. The reporting period covers the fiscal year ended December 28, 2001.
Key Financial Metrics
| Metric | 2001 | 2000 |
|---|---|---|
| Total Revenues | $50.8 million | $54.4 million |
| Gross Profit | $22.6 million (44.5% margin) | $28.1 million (51.6% margin) |
| Net Loss | $(14.8) million ($(0.87) per share) | $(18.9) million ($(1.23) per share) |
| Operating Cash Flow | $(2.6) million used | $(5.4) million used |
| Working Capital | $17.1 million | $24.3 million |
| Cash and Equivalents | $0.9 million | $6.1 million |
| Total Debt (Notes Payable) | $8.2 million | $7.9 million |
Material Changes vs. Prior Period
- Revenue Decline: Revenues decreased 7% to $50.8 million, primarily due to a voluntary recall of silicone IOLs in Q2 2001 and reduced sales of the SonicWAVE Phacoemulsification System following the elimination of a dedicated sales force.
- Restructuring Charges: The company recorded $7.8 million in pretax restructuring charges in Q3 and Q4 2001, including $3.7 million in fixed asset write-offs, $1.0 million for subsidiary closures, and $0.3 million in severance.
- Inventory Write-offs: A $6.4 million inventory write-off related to voluntary product recalls and excess/obsolete inventory was included in cost of sales, significantly impacting gross margins.
- Adjusted Performance: Excluding $14.2 million in nonrecurring charges (restructuring and inventory write-offs), the net loss for 2001 was $1.6 million, compared to a $0.8 million loss in 2000.
- Joint Venture Resolution: A dispute with Canon Inc. regarding the Japanese joint venture was settled in September 2001, resulting in a $280,000 dividend and the dismissal of legal actions.
Outlook, Risks, and Management Commentary
- Profitability Plan: Management implemented a restructuring plan in August 2001 to consolidate manufacturing (moving lathing to Switzerland) and reduce workforce to achieve profitability.
- Regulatory Milestones: The company received FDA pre-market approval for the AquaFlow Device in July 2001 and a conditional IDE for the Toric ICL in January 2002. The company anticipates filing for ICL pre-market approval in 2002.
- Liquidity and Debt: As of December 28, 2001, the company was not in compliance with the net income covenant of its domestic line of credit, though the lender agreed to a waiver. A commitment letter dated March 27, 2002, indicates an agreement to extend the credit line maturity for one year, subject to conditions.
- Risks: Key risks include the acceptance of newer products, regulatory approval timelines, reimbursement policy changes, and foreign currency fluctuations. The company does not currently hedge foreign currency exposure.
Investor Verification Checklist
- Debt Covenant Compliance: Verify the final terms of the credit line extension and the company's ability to meet future covenants given the recent net losses.
- Inventory Valuation: Assess the remaining inventory levels and the risk of further write-offs following the $6.4 million charge in 2001.
- Product Mix Shift: Monitor the transition from silicone IOLs to Collamer and Toric IOLs to ensure the anticipated margin recovery materializes.
- Regulatory Approvals: Track the status of the ICL pre-market approval application expected in 2002, which is critical for growth in the refractive market.
- Cash Burn Rate: Review the reduction in cash from $6.1 million to $0.9 million and the adequacy of remaining liquidity to fund operations without further equity dilution.